Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...
Amyloidosis occurs when a protein called amyloid builds up in organs such as the heart, kidneys, liver, nerves, and digestive system. Deposits may be body-wide or localized and can lead to organ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results